Jarkko Kalliomäki

TL;DR: In this paper, the authors present recommendations for the major components of confirmatory chronic pain clinical trials, including participant selection, trial phases and duration, treatment groups and dosing regimens, and types of trials.

TL;DR: The CCR2 antagonist AZD2423 demonstrated no efficacy on NRS average pain scores and most of the secondary pain variables, and the NPSI data suggested possible effects on certain sensory components of pain.

TL;DR: The emergence of mild dose‐dependent CNS effects suggests that the dose range predicted from preclinical data had been attained, and no evidence of analgesic efficacy was found for a peripherally acting CB1/CB2 receptor agonist in the human capsaicin pain model.

TL;DR: The CB1/CB2 receptor agonist AZD1940 did not reduce post-operative pain after lower third molar surgical removal at doses exerting subjective cannabinoid effects, and increases in VAMS were numerically small compared with previous findings with a centrally acting cannabinoid.

TL;DR: It is demonstrated that acute doses of nabilone in the range 1—3 mg produce clear cognitive and subjective effects in healthy volunteers, and therefore they may be used as reference data in the future study of peripherally acting cannabinoids believed to be free from such effects.